Medical device company Thoratec (NSDQ:THOR) took a harsh blow from Wall Street after releasing its Q1 earnings report, with shares down more than 10% by mid-day.
2013
Allergan rebounds after Q1 numbers send shares down 13%
Allergan (NYSE:AGN) took a ride on the wild side this week as Wall Street pounded the medical aesthetics company after its 1st-quarter earnings release, initially sending share down more than 13%.
Some of the selloff appeared related to news that Irvine, Calif.-based Allergan is delaying the rollout of Darpin, its macular degeneration drug. Investors were also spooked by lowered guidance for 2013 and a bottom-line writedown over the sale of its Lap-Band business.
Haemonetics plans to cut 320 jobs, move manufacturing to Mexico, Asia
Haemonetics (NYSE:HAE) said it plans to shutter manufacturing operations in its Massachusetts home base and shift them to Mexico and Asia, reportedly cutting 320 jobs in the process.
Siemens Healthcare’s Q2 profits rise despite declining sales
Medical device tax cut about 4% from Q2 earnings growth, Becton Dickinson reports
Healthcare giant Becton Dickinson & Co. (NYSE:BDX) posted some ups and downs for its 2nd quarter of 2013, exceeding analysts’ expectations on earnings but taking some hits with lowered medical device sales and a nearly 4% cut in earnings growth due to the medical device tax.
NxStage Medical gains on pared Q1 losses, sales growth, affirmed guidance
NxStage Medical (NSDQ:NXTM) shares are up more than 5% today after the medical device company reported 1st-quarter sales growth and lower losses and affirmed its outlook for the rest of 2013.
Smith & Nephew buys into India, announces $300M share buyback as Q1 profits slide on flat sales
Abiomed gains on surging FY2013 profits
Abiomed (NSDQ:ABMD) shares gained nearly 7% this morning after the medical device company reported profit growth in excess of 900%, beating Wall Street’s earnings expectations along the way.
The Danvers, Mass.-based heart pump maker reported fiscal 2013 profits of $15.0 million, or 38¢ per share, on sales of $157.6 million, for a whopping bottom-line gain of 904.3% on top-line growth of 25.8%.
Cynosure’s Q1 earnings miss expectations
LeMaitre Vascular ticks up on 120% Q1 profit jump
Profits soared 120% for LeMaitre Vascular (NSDQ:LMAT) during the 1st quarter on its 2nd consecutive quarter of double-digit sales growth, as the medical device company beat Wall Street’s earnings expectations by a penny.